• Hereditary Diffuse Gastric Cancer.
    • Decourtye-Espiard L, Guilford P.
    • Gastroenterology. 2023 Feb 3:S0016-5085(23)00110-5. doi: 10.1053/j.gastro.2023.01.038. Epub ahead of print.
    • Review
    • Update: Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations.
    • [No author given]
    • FORCE. XRAY. 2023 Jan 9.

    Related:

    •• Identifier: NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)

    • Reducing the risk of breast cancer.
    • Pederson HJ, Al-Hilli Z, Kurian AW.
    • Cleve Clin J Med. 2022 Nov 1;89(11):643-652. doi: 10.3949/ccjm.89a.21113.
    • Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.
    • Nemati Shafaee M, Goutsouliak K, Lin H, Bevers TB, Gutierrez-Barrera A, Bondy M, Arun B.
    • Breast Cancer Res Treat. 2022 Nov;196(1):143-152. doi: 10.1007/s10549-022-06688-z. Epub 2022 Aug 25.
    • Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
    • Evron E, Ben-David MA, Kaidar-Person O, Corn BW.
    • J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609. Epub ahead of print.
    • Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    • Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
    • Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.
    • Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
    • Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S.
    • Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057.
    • Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.
    • Bernstein-Molho R, Friedman E, Evron E.
    • Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592.
    • Breast cancer risk reduction: who, why, and what?
    • Bozzuto LM.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Sep;83:36-45. doi: 10.1016/j.bpobgyn.2021.11.012. Epub 2021 Dec 8.
    • Review
    • Optimal breast cancer risk reduction policies tailored to personal risk level.
    • Ergun MA, Hajjar A, Alagoz O, Rampurwala M.
    • Health Care Manag Sci. 2022 Sep;25(3):363-388. doi: 10.1007/s10729-022-09596-2. Epub 2022 Jun 10.
    • Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy.
    • Trivedi MS, Arber N, Friedman E, Garber JE, Holcomb K, Horowitz NS, Wright JD, Lee JJ, Vornik LA, Abutaseh S, Castile T, Sauter ER, Dimond E, Heckman-Stoddard BM, House M, Samimi G, Brown PH, Crew KD.
    • Cancer Prev Res (Phila). 2022 Aug 24:OF1-OF6. doi: 10.1158/1940-6207.CAPR-22-0051. Epub ahead of print.
    • Commentary

    Related:

    Identifier: NCT03382574: Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy. (ClinicalTrials.gov)

    • Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
    • Hurwitz LM, Townsend MK, Jordan SJ, Patel AV, Teras LR, Lacey JV Jr, Doherty JA, Harris HR, Goodman MT, Shvetsov YB, Modugno F, Moysich KB, Robien K, Prizment A, Schildkraut JM, Berchuck A, Fortner RT, Chan AT, Wentzensen N, Hartge P, Sandler DP, O'Brien KM, Anton-Culver H, Ziogas A, Menon U, Ramus SJ, Pearce CL, Wu AH, White E, Peters U, Webb PM, Tworoger SS, Trabert B.
    • J Clin Oncol. 2022 Jul 22:JCO2101900. doi: 10.1200/JCO.21.01900. Epub ahead of print.
    • Meta-Analysis
    • The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study.
    • Forrest LE, Forbes Shepherd R, Tutty E, Pearce A, Campbell I, Devereux L, Trainer AH, James PA, Young MA.
    • J Pers Med. 2022 Jul 7;12(7):1112. doi: 10.3390/jpm12071112.
    • Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland.
    • Bommer C, Lupatsch J, Bürki N, Schwenkglenks M.
    • Eur J Health Econ. 2022 Jul;23(5):807-821. doi: 10.1007/s10198-021-01396-9. Epub 2021 Nov 12.
    • Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers.
    • Su Y, Dang NM, Depypere H, Santucci-Pereira J, Gutiérrez-Díez PJ, Kanefsky J, Janssens JP, Russo J.
    • Eur J Cancer Prev. 2022 Jun 30. doi: 10.1097/CEJ.0000000000000763. Epub ahead of print.
    • Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
    • Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M.
    • Genome Med. 2022 Jun 15;14(1):64. doi: 10.1186/s13073-022-01063-5.

    Related:

    EudraCT number: 2009-009014-40: Pre-treatment with Mifepristone prior to Mirena insertion for optimizing bleeding pattern in pre-menopausal women. (EU Clinical Trials Register)

    Identifier: NCT01898312: BRCA1/2 and Effect of Mifepristone on the Breast. (ClinicalTrials.gov)

    EudraCT number: 2015-001587-19: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk. (EU Clinical Trials Register)

    • Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
    • Park J, Huang D, Chang YJ, Lim MC, Myung SK.
    • Carcinogenesis. 2022 Apr 25;43(3):231-242. doi: 10.1093/carcin/bgab107.
    • Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.
    • Park SS, Uzelac A, Kotsopoulos J.
    • Hered Cancer Clin Pract. 2022 Apr 13;20(1):14. doi: 10.1186/s13053-022-00223-3.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 11.

    Related:

    Identifier: NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers. (ClinicalTrials.gov)

    • Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
    • Fang SY, Hsieh LL, Hung CF, Hung FH, Peng HP, Yang AS, Wang YA.
    • Support Care Cancer. 2022 Apr;30(4):3625-3632. doi: 10.1007/s00520-021-06742-4. Epub 2022 Jan 14.
    • Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.
    • Clarfield L, Diamond L, Jacobson M.
    • Curr Oncol. 2022 Mar 21;29(3):2132-2140. doi: 10.3390/curroncol29030172.
    • Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations.
    • Horton C, Blanco K, Lo MT, Speare V, LaDuca H, Dolinsky JS, Kurian AW.
    • JNCI Cancer Spectr. 2022 Mar 2;6(2):pkac002. doi: 10.1093/jncics/pkac002.
    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Genetic predisposition to prostate cancer: an update.
    • Ni Raghallaigh H, Eeles R.
    • Fam Cancer. 2022 Jan;21(1):101-114. doi: 10.1007/s10689-021-00227-3. Epub 2021 Jan 24.
    • Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study.
    • Sina F, Cassani C, Comerio C, De Ponti E, Zanellini F, Delle Marchette M, Roversi G, Jaconi M, Arbustini E, Urtis M, Dell'Oro C, Zambetti B, Paniga C, Acampora E, Negri S, Lazzarin S, Cesari S, Spinillo A, Kotsopoulos J, Fruscio R.
    • Int J Gynecol Cancer. 2022 Jan;32(1):41-47. doi: 10.1136/ijgc-2021-003153. Epub 2021 Nov 29.
    • Prolonged recombinant pregnancy hormone use for breast cancer prevention in BRCA1 And 2 mutation carriers.
    • Depypere H, Su Y, Dang N, Poppe B, Stanczyk FZ, Janssens J, Russo J.
    • Eur J Cancer Prev. 2021 Dec 1;31(Suppl 1):S3-S4. doi: 10.1097/01.cej.0000816644.52776.6e. Epub 2021 Dec 30.
    • An Update on the effect of Recombinant Human Chorionic Gonadotropin in Breast Cancer Prevention.
    • Russo J.
    • Eur J Cancer Prev. 2021 Dec 1;31(Suppl 1):S4-S5. doi: 10.1097/01.cej.0000816656.58097.71. Epub 2021 Dec 30.
    • Underutilisation of breast cancer prevention medication in Australia.
    • Macdonald C, Chamberlain JA, Mazza D, Milne RL; kConFab investigators, Phillips KA.
    • Breast. 2021 Dec;60:35-37. doi: 10.1016/j.breast.2021.08.013. Epub 2021 Aug 23.
    • Mutations in BRCA1 or BRCA2 may increase risk for endometrial cancer.
    • [No author given]
    • FORCE. XRAY. 2021 Nov 30.

    Related:

    Original research:

    Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.

    • Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?
    • Stern T, Peleg Hasson S, Saad A, Levanon K, Michaan N, Laskov I, Wolf I, Safra T.
    • Gynecol Oncol Rep. 2021 Sep 20;38:100863. doi: 10.1016/j.gore.2021.100863. eCollection 2021 Nov.
    • Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    • de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, Gómez Garcia EB, Ausems MGEM, Margriet Collée J, van Engelen K, van de Beek I; Hebon Group, Smit VTHBM, Rookus MA, de Bock GH, van Leeuwen FE, Bosse T, Dekkers OM, van Asperen CJ.
    • J Natl Cancer Inst. 2021 Sep 4;113(9):1203-1211. doi: 10.1093/jnci/djab036.

    Related:

    Commentary:

    BRCA1/2 and Endometrial Cancer Risk: Implications for Management.

    Letter, Commentary:

    RE: Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.

    Letter, Reply:

    Response to Nahshon and Lavie.

    Research news: Study: Mutations in BRCA1 or BRCA2 may increase risk for endometrial cancer. (FORCE. XRAY.)

    • RE: Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    • Nahshon C, Lavie O.
    • J Natl Cancer Inst. 2021 Aug 23:djab154. doi: 10.1093/jnci/djab154. Epub ahead of print.

    Related:

    Letter, Reply:

    Response to Nahshon and Lavie.

    Original research:

    Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.

    • Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours.
    • Bellhouse S, Hawkes RE, Howell SJ, Gorman L, French DP.
    • Cancers (Basel). 2021 Aug 18;13(16):4150. doi: 10.3390/cancers13164150.
    • Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
    • Lloyd KE, Hall LH, Ziegler L, Smith SG; ENGAGE investigators.
    • Breast Cancer Res Treat. 2021 Aug;188(3):703-712. doi: 10.1007/s10549-021-06183-x. Epub 2021 Mar 17.
    • Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    • Lee O, Bosland MC, Wang M, Shidfar A, Hosseini O, Xuei X, Patel P, Schipma MJ, Helenowski I, Kim JJ, Clare SE, Khan SA.
    • Cancer Lett. 2021 Jul 27:S0304-3835(21)00361-X. doi: 10.1016/j.canlet.2021.07.034. Epub ahead of print.
    • The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
    • Smith SG, Sestak I, Morris MA, Harvie M, Howell A, Forbes J, Cuzick J.
    • Breast Cancer Res Treat. 2021 Jul;188(1):215-223. doi: 10.1007/s10549-021-06141-7. Epub 2021 Mar 3.
    • Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
    • Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ.
    • NPJ Breast Cancer. 2021 Jun 17;7(1):78. doi: 10.1038/s41523-021-00288-8.
    • Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review.
    • Krassuski LM, Kautz-Freimuth S, Vennedey V, Rhiem K, Schmutzler RK, Stock S.
    • Geburtshilfe Frauenheilkd. 2021 Jun;81(6):679-698. doi: 10.1055/a-1326-1792. Epub 2021 Jun 21.
    • Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers.
    • Depypere H, Su Y, Dang N, Poppe B, Stanczyk F, Janssens J, Russo J.
    • Eur J Cancer Prev. 2021 May 1;30(3):195-203. doi: 10.1097/CEJ.0000000000000664.
    • Screening High-Risk Women Veterans for Breast Cancer.
    • Park YA, Keller A, Hsu TM, Bidassie B, Venne V, Hawley D, Hoffman-Högg L, Heron B, Colonna S, Aggarwal A.
    • Fed Pract. 2021 May;38(Suppl 2):S35-S41. doi: 10.12788/fp.0122.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.
    • Meiser B, Kaur R, Morrow A, Peate M, Wong WKT, McPike E, Cops E, Nichols C, Austin R, Fine M, Thrupp L, Ward R, Macrae F, Hiller JE, Trainer AH, Mitchell G; ICCon Audit Study Collaborative Group.
    • Hered Cancer Clin Pract. 2021 Apr 9;19(1):24. doi: 10.1186/s13053-021-00180-3.
    • Controversies in Hereditary Cancer Management.
    • AlHilli MM, Pederson HJ.
    • Obstet Gynecol. 2021 Apr 8. doi: 10.1097/AOG.0000000000004364. Epub ahead of print.
    • Why So Many of Us Quit Taking Tamoxifen.
    • Horner K.
    • FORCE. Blog. 2021 Apr 6.

    Related:

    Research news: Study: How breast cancer patients experience hormone therapy (FORCE. XRAY.)

    • Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers.
    • Singer CF.
    • Breast Care (Basel). 2021 Apr;16(2):144-148. doi: 10.1159/000507503. Epub 2020 May 11.
    • Review
    • Determinants of serum adiponectin levels: a cross-sectional study.
    • Sattarinezhad A, Rasekhi Kazerouni A, Omrani GR, Shams M.
    • Horm Mol Biol Clin Investig. 2021 Mar 31;42(3):321-324. doi: 10.1515/hmbci-2020-0057.
    • Assessing Risk of Breast Cancer: A Review of Risk Prediction Models.
    • Kim G, Bahl M.
    • J Breast Imaging. 2021 Feb 19;3(2):144-155. doi: 10.1093/jbi/wbab001. eCollection Mar-Apr 2021.
    • Review
    • Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.
    • Kim JO, Schaid DJ, Vachon CM, Cooke A, Couch FJ, Kim CA, Sinnwell JP, Hasadsri L, Stan DL, Goldenberg B, Neal L, Grenier D, Degnim AC, Thicke LA, Pruthi S.
    • Cancer Prev Res (Phila). 2021 Feb;14(2):175-184. doi: 10.1158/1940-6207.CAPR-20-0154. Epub 2020 Oct 23.
    • Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community.
    • Laws A, Mulvey TM.
    • JCO Oncol Pract. 2021 Feb;17(2):e217-e225. doi: 10.1200/OP.20.00256. Epub 2020 Aug 21.
    • Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
    • Zhang D, Singh B, Moerland J, Mitchell O, Lockwood L, Carapellucci S, Sridhar S, Liby KT.
    • Sci Rep. 2021 Jan 13;11(1):1234. doi: 10.1038/s41598-020-79663-7.
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey.
    • Jones S, Hogan B, Patel K, Ooi S, Turton P, Achuthan R, Kim B.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06046-x. Epub ahead of print.
    • Breast Cancer Chemoprevention: Use and Views of Australian Women and their Clinicians.
    • Macdonald C, Saunders CM, Keogh LA, Hunter M, Mazza D, McLachlan SA, Jones SC, Nesci S, Friedlander ML, Hopper JL, Emery JD, Hickey M, Milne RL, Phillips KA; Kathleen Cuningham Consortium for Research Into Familial Breast Cancer.
    • Cancer Prev Res (Phila). 2021 Jan;14(1):131-144. doi: 10.1158/1940-6207.CAPR-20-0369. Epub 2020 Oct 28.

    Related:

    Commentary:

    Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue.

    • Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England.
    • Lee SI, Curtis H, Qureshi S, Dutton B, Qureshi N.
    • J Community Genet. 2021 Jan;12(1):111-120. doi: 10.1007/s12687-020-00490-4. Epub 2020 Oct 28.
    • Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020).
    • Howell A, Gandhi A, Howell S, Wilson M, Maxwell A, Astley S, Harvie M, Pegington M, Barr L, Baildam A, Harkness E, Hopwood P, Wisely J, Wilding A, Greenhalgh R, Affen J, Maurice A, Cole S, Wiseman J, Lalloo F, French DP, Evans DG.
    • Cancers (Basel). 2020 Dec 9;12(12):3697. doi: 10.3390/cancers12123697.
    • Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis.
    • Lu G, Lu T, Pan J, Guo L, Pang Y, Liu P.
    • Arch Gynecol Obstet. 2020 Nov 20. doi: 10.1007/s00404-020-05887-7.
    • Review
    • Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers.
    • Pejovic T, Joshi S, Campbell S, Thisted S, Xu F, Xu J.
    • Oncotarget. 2020 Nov 10;11(45):4104-4114. doi: 10.18632/oncotarget.27803.
    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review
    • Young women's decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk: a qualitative study.
    • Forrest LE, Shepherd RF, Young MA, Keogh LA, James PA.
    • Psychooncology. 2020 Oct 1. doi: 10.1002/pon.5556. Epub ahead of print.
    • Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
    • Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Lynch HT, Narod SA, Evans DG, Liede A.
    • Hered Cancer Clin Pract. 2020 Sep 29;18:20. doi: 10.1186/s13053-020-00152-z.
    • Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease.
    • Cen C, Chun J, Schnabel F.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13964. Online ahead of print.
    • Review
    • Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
    • Wood ME, McKinnon W, Garber J.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13969. Epub ahead of print.
    • Review
    • Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.
    • Chelmow D, Pearlman MD, Young A, Bozzuto L, Dayaratna S, Jeudy M, Kremer ME, Scott DM, O'Hara JS.
    • Obstet Gynecol. 2020 Jun;135(6):1457-1478. doi: 10.1097/AOG.0000000000003889.
    • 3,3-Diindolylmethane (DIM): A nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial.
    • Yerushalmi R, Bargil S, Bar Y, Ozlavo R, Tuval S, Rapson Y, Pomerantz A, Zoref D, Sharon E, Caspi O, Grubsrein A, Margel D.
    • Carcinogenesis. 2020 May 27:bgaa050. doi: 10.1093/carcin/bgaa050. Epub ahead of print. PMID: 32458980.
    • Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy.
    • Blasiak J, Pawlowska E, Chojnacki J, Szczepanska J, Fila M, Chojnacki C.
    • Int J Mol Sci. 2020 May 23;21(10):E3670. doi: 10.3390/ijms21103670.
    • Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes.
    • Singer CF.
    • Horm Mol Biol Clin Investig. 2020 May 7;41(3):/j/hmbci.2020.41.issue-3/hmbci-2019-0057/hmbci-2019-0057.xml. doi: 10.1515/hmbci-2019-0057.
    • Review
    • Updated Guideline Moves Genetic Testing Beyond BRCA.
    • Narozniak R.
    • OncologyLive. 2020 Mar 13;21(6).
    • News

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    • Printz C.
    • Cancer. 2020 Feb 15;126(4):693. doi: 10.1002/cncr.32723.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
    • Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR.
    • J Pers Med. 2020 Feb 3;10(1). pii: E7. doi: 10.3390/jpm10010007.
    • BRCA1/P53: Two strengths in cancer chemoprevention.
    • Raimundo L, Ramos H, Loureiro JB, Calheiros J, Saraiva L.
    • Biochim Biophys Acta Rev Cancer. 2020 Jan 6:188339. doi: 10.1016/j.bbcan.2020.188339. [Epub ahead of print]
    • Breast cancer risk reduction: Notable achievements and remaining challenges.
    • Vogel VG.
    • Breast J. 2020 Jan;26(1):86-91. doi: 10.1111/tbj.13717.
    • SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
    • González-Santiago S, Ramón Y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, Graña B, Herrero A, Llort G, González-Del-Alba A; SEOM Hereditary Cancer Working Group.
    • Clin Transl Oncol. 2019 Dec 30. doi: 10.1007/s12094-019-02262-0. [Epub ahead of print]
    • USPSTF guideline: Offer risk-reducing drugs to women at increased risk for breast cancer and low risk for adverse effects.
    • Batur P.
    • Ann Intern Med. 2019 Dec 17;171(12):JC62. doi: 10.7326/ACPJ201912170-062.
    • Review

    Related:

    Practice Guidelines:

    Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.

    • Breast cancer prevention in high-risk women.
    • Thorat MA, Balasubramanian R.
    • Best Pract Res Clin Obstet Gynaecol. 2019 Nov 21. pii: S1521-6934(19)30170-1. doi: 10.1016/j.bpobgyn.2019.11.006. [Epub ahead of print]
    • Review
    • Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.
    • [No author given]
    • National Institute for Health and Care Excellence (UK): Clinical Guidelines; 2013 Jun. [Last Update: November 2019.]
    • Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB.
    • JAMA. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885.

    Related:

    Guidelines:

    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Editorial:

    Medications to Reduce Breast Cancer Risk: Promise and Limitations.

    Patient Page:

    Medications to Reduce Breast Cancer Risk.

    Audio Interview/CME: USPSTF Recommendation: Medication Use to Reduce Risk of Breast Cancer. (JN Learning)

    Review:

    USPSTF guideline: Offer risk-reducing drugs to women at increased risk for breast cancer and low risk for adverse effects.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Related:

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
    • Wang T, McCullough LE, White AJ, Bradshaw PT, Xu X, Cho YH, Terry MB, Teitelbaum SL, Neugut AI, Santella RM, Chen J, Gammon MD.
    • Cancer. 2019 Aug 12. doi: 10.1002/cncr.32364. [Epub ahead of print]
    • Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.
    • Walker M, Jacobson M, Sobel M.
    • CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • Hormone-based strategies for management of BrCa1 and 2 carriers.
    • Santen R.
    • Maturitas. 2019 Jun;124:120-121. doi: 10.1016/j.maturitas.2019.04.034.
    • Conference abstract, Review
    • Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
    • Zhou Y, Simmons J, Jordan CD, Sonbol MB, Maihle N, Tang SC.
    • Clin Breast Cancer. 2019 May 18. pii: S1526-8209(19)30066-7. doi: 10.1016/j.clbc.2019.05.004. [Epub ahead of print]
    • Factors associated with intentions for breast cancer risk management: Does risk group matter?
    • Conley CC, Agnese DM, Vadaparampil ST, Andersen BL.
    • Psychooncology. 2019 May;28(5):1119-1126. doi: 10.1002/pon.5066. Epub 2019 Apr 10.
    • Chemoprevention acceptance and adherence in women with high-risk breast lesions.
    • Roche CA, Tang R, Coopey SB, Hughes KS.
    • Breast J. 2019 Mar;25(2):190-195. doi: 10.1111/tbj.13064. Epub 2018 May 21

    Related:

    Editorial:

    Applying the Hippocratic Oath in breast cancer-The case for promoting prevention.

    Press: Chemoprevention of Breast Cancer: Personal Touch Helps Uptake. (Medscape Oncology)

    • Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1-/2- carriers.
    • Ponandai-Srinivasan S, Lalitkumar PG, Garcia L, Varghese SJ, Carlson JW, Gemzell-Danielsson K, Floter Radestad A.
    • Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.
    • Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
    • Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D.
    • Curr Oncol. 2019 Feb;26(1):e17-e23. doi: 10.3747/co.26.4068. Epub 2019 Feb 1.
    • Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.
    • Sutherland S, Meiser B, Kaur R, Mitchell G, Kirk J, Peate M, Tim Wong WK, Goodwin A.
    • Breast J. 2019 Jan;25(1):34-40. doi: 10.1111/tbj.13157. Epub 2018 Dec 7.

  92. Related:

    Press: USPSTF Reaffirms Drugs for Women at High Risk for Breast Cancer. (Medscape Oncology)

    • Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    • Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R.
    • Ann Ital Chir. 2019;90:1-2.
    • Review
    • Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
    • Campbell AM, Morris M, Gallagher R, Boyd R, Carson H, Harkin DP, Wielogorska E, Elliott C, Savage KI, McIntosh SA.
    • BMJ Open. 2018 Dec 22;8(12):e023115. doi: 10.1136/bmjopen-2018-023115.
    • CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
    • Brooks JD, Comen EA, Reiner AS, Orlow I, Leong SF, Liang X, Mellemkjær L, Knight JA, Lynch CF, John EM, Bernstein L, Woods M, Doody DR; WECARE Study collaborative group, Malone KE, Bernstein JL.
    • Breast Cancer Res. 2018 Dec 10;20(1):149. doi: 10.1186/s13058-018-1083-y.
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    Related:

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors.
    • Baek HJ, Kim SE, Kim JK, Shin DH, Kim TH, Kim KG, Deng CX, Kim SS.
    • Int J Biol Sci. 2018 Oct 3;14(13):1769-1781. doi: 10.7150/ijbs.29242. eCollection 2018.
    • Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation.
    • Baek HJ, Kim SE, Choi EK, Kim JK, Shin DH, Park EJ, Kim TH, Kim JY, Kim KG, Deng CX, Kim SS.
    • Int J Biol Sci. 2018 Oct 3;14(12):1755-1768. doi: 10.7150/ijbs.28142. eCollection 2018.
    • Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.
    • Jatoi I.
    • Eur J Breast Health. 2018 Oct 1;14(4):189-193. doi: 10.5152/ejbh.2018.4324. eCollection 2018 Oct.

    Related:

    Letter, Review:

    What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers.

    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • Personalized prevention in high risk individuals: Managing hormones and beyond.
    • Evans DG, Howell SJ, Howell A.
    • Breast. 2018 Jun;39:139-147. doi: 10.1016/j.breast.2018.03.009. Epub 2018 Mar 30.
    • Review
    • Ovarian Cancer Prevention and Screening.
    • Menon U, Karpinskyj C, Gentry-Maharaj A.
    • Obstet Gynecol. 2018 May;131(5):909-927. doi: 10.1097/AOG.0000000000002580.
    • Review
    • Germline BRCA mutation in male carriers-ripe for precision oncology?
    • Leão RRN, Price AJ, James Hamilton R.
    • Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.
    • Review
    • RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
    • Rao S, Cronin SJF, Sigl V, Penninger JM.
    • Trends Cell Biol. 2018 Mar;28(3):213-223. doi: 10.1016/j.tcb.2017.11.001. Epub 2017 Dec 11.
    • Review
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network.
    • Harvey LFB, Abramson VG, Alvarez J, DeStephano C, Hur HC, Lee K, Mattingly P, Park B, Piszczek C, Seifi F, Stuparich M, Yunker A.
    • J Minim Invasive Gynecol. 2018 Jan;25(1):111-115. doi: 10.1016/j.jmig.2017.08.643. Epub 2017 Aug 15.
    • Surveillance report 2018 – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2013) NICE guideline CG164 [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Murray A.
    • London: National Institute for Health and Care Excellence (UK); 2018 Jan.

    • The Chemoprevention of Ovarian Cancer: the Need and the Options.
    • Kathawala RJ, Kudelka A, Rigas B.
    • Curr Pharmacol Rep. 2018;4(3):250-260. doi: 10.1007/s40495-018-0133-6. Epub 2018 May 2.
    • The Preventive Intervention of Hereditary Breast Cancer.
    • Cao A, Huang L, Shao Z.
    • Adv Exp Med Biol. 2017 [2017 Dec 28];1026:41-57. doi: 10.1007/978-981-10-6020-5_3.
    • Review
    • Prophylaxis of hereditary breast cancer.
    • de Groot JS, van Diest PJ, Derksen PWB.
    • Aging (Albany NY). 2017 Dec 8;9(12):2453-2454. doi: 10.18632/aging.101342.
    • Experiencing the cancer of a loved one influences decision-making for breast cancer prevention.
    • Padamsee TJ, Muraveva A, Yee LD, Wills CE, Paskett ED.
    • J Health Psychol. 2017 Dec 1:1359105317746480. doi: 10.1177/1359105317746480. [Epub ahead of print]
    • Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.
    • Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, Bandos H, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C.
    • Patient Educ Couns. 2017 Dec;100(12):2346-2354. doi: 10.1016/j.pec.2017.06.033. Epub 2017 Jun 27.
    • Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
    • Mazumder S, Johnson JM, Swank V, Dvorina N, Martelli E, Ko J, Tuohy VK.
    • Cancer Prev Res (Phila). 2017 Nov;10(11):612-624. doi: 10.1158/1940-6207.CAPR-17-0154.

    Related:

    Editorial:

    Targeting "Retired Antigens" for Cancer Immunoprevention.

    • Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer.
    • Hermel DJ, Wood ME, Chun J, Rounds T, Sands M, Schwartz S, Schnabel FR.
    • Clin Breast Cancer. 2017 Oct;17(6):427-432. doi: 10.1016/j.clbc.2017.04.005. Epub 2017 Apr 14.
    • Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
    • Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    • Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.
    • Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.
    • Meiser B, Wong WKT, Peate M, Julian-Reynier C, Kirk J, Mitchell G.
    • Hered Cancer Clin Pract. 2017 Sep 20;15:14. doi: 10.1186/s13053-017-0075-8. eCollection 2017.
    • Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    • Liede A, Mansfield CA, Metcalfe KA, Price MA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG.
    • Breast Cancer Res Treat. 2017 Sep;165(2):433-444. doi: 10.1007/s10549-017-4332-3. Epub 2017 Jun 17.
    • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
    • Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.
    • Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.
    • Risk Reduction Strategies in Breast Cancer Prevention.
    • Costa M, Saldanha P.
    • Eur J Breast Health. 2017 Jul 1;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul.
    • Managing hereditary breast cancer risk in women with and without ovarian cancer.
    • Peters ML, Garber JE, Tung N.
    • Gynecol Oncol. 2017 Jul;146(1):205-214. doi: 10.1016/j.ygyno.2017.04.013. Epub 2017 Apr 25.
    • Review
    • Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.
    • de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.
    • Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.
    • Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
    • Cuyàs E, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    • Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement.
    • Pérez-López FR, Ceausu I, Depypere H, Kehoe S, Lambrinoudaki I, Mueck A, Senturk LM, Simoncini T, Stevenson JC, Stute P, Rees M.
    • Maturitas. 2017 Jun;100:86-91. doi: 10.1016/j.maturitas.2017.03.003. Epub 2017 Mar 15.
    • BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
    • Cuyàs E, Corominas-Faja B, Muñoz-San Martín M, Martin-Castillo B, Lupu R, Brunet J, Bosch-Barrera J, Menendez JA.
    • Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.
    • Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
    • Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB.
    • Breast. 2017 Apr;32:93-97. doi: 10.1016/j.breast.2017.01.002. Epub 2017 Jan 18.
    • Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
    • Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.
    • Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6.
    • Decision making for breast cancer prevention among women at elevated risk.
    • Padamsee TJ, Wills CE, Yee LD, Paskett ED.
    • Breast Cancer Res. 2017 Mar 24;19(1):34. doi: 10.1186/s13058-017-0826-5.
    • Prophylactic window therapy with the clinical PARP inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    • van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.
    • J Pathol. 2017 Mar;241(4):511-521. doi: 10.1002/path.4857. Epub 2017 Jan 23.
    • Addendum to Clinical Guideline 164, Familial breast cancer..
    • National Institute for Health and Care Excellence (UK) Standing Committee and NICE Teams.
    • National Institute for Health and Care Excellence (UK); 2017 Mar.
    • An exploratory study of patients' views about being at high-risk for breast cancer and risk management beliefs and intentions, before and after risk counselling: Preliminary evidence of the influence of beliefs on post-counselling prevention intentions.
    • Paquet L, Simmonds L, Yang C, Verma S.
    • Patient Educ Couns. 2017 Mar;100(3):575-582. doi: 10.1016/j.pec.2016.10.005. Epub 2016 Oct 11.
    • Out-RANKing BRCA1 in Mutation Carriers.
    • Nolan E, Lindeman GJ, Visvader JE.
    • Cancer Res. 2017 Feb 1;77(3):595-600. doi: 10.1158/0008-5472.CAN-16-2025. Epub 2017 Jan 19.
    • Review
    • Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    • Bayer CM, Beckmann MW, Fasching PA.
    • Curr Opin Obstet Gynecol. 2017 Feb;29(1):4-11. doi: 10.1097/GCO.0000000000000333.
    • Review
    • [Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].
    • Kida K, Murai M, Yamauchi H.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):111-115.
    • Review, [Article in Japanese]
    • Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.
    • Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K.
    • PLoS One. 2017 Jan 20;12(1):e0168601. doi: 10.1371/journal.pone.0168601. eCollection 2017.
    • Chemopreventive effects of ROS targeting in a murine model of BRCA1-deficient breast cancer.
    • Li M, Yu X, Chen Q.
    • Cancer Res. 2017 Jan 15;77(2):448-458. doi: 10.1158/0008-5472.CAN-16-2350. Epub 2016 Nov 4.
    • Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    • Kotsopoulos J, Singer C, Narod SA.
    • Breast Cancer Res Treat. 2017 Jan;161(1):11-16. doi: 10.1007/s10549-016-4029-z. Epub 2016 Oct 25.
    • Review
    • Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    • Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, Salmena L, Kotsopoulos J.
    • Oncotarget. 2016 Dec 27;7(52):86687-86694. doi: 10.18632/oncotarget.13417.
    • Prevention of breast cancer.
    • Olver IN.
    • Med J Aust. 2016 Nov 21;205(10):475-479.
    • Review
    • RANKL/RANK: from bone loss to the prevention of breast cancer.
    • Sigl V, Jones LP, Penninger JM.
    • Open Biol. 2016 Nov;6(11). pii: 160230.
    • Management of women with a hereditary predisposition for breast cancer.
    • Jatoi I, Benson JR.
    • Future Oncol. 2016 Oct;12(19):2277-88. doi: 10.2217/fon-2016-0186. Epub 2016 Jul 7.
    • Review
    • Pharmacoprevention for hereditary breast and ovarian cancer.
    • Cazzaniga M, Bonanni B.
    • Minerva Ginecol. 2016 Oct;68(5):517-35. Epub 2016 Feb 29.
    • Review
    • Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report.
    • Signorelli M, Bogani G, Ditto A, Martinelli F, Chiappa V, Lopez C, Scaffa C, Lorusso D, Raspagliesi F.
    • Minerva Ginecol. 2016 Oct;68(5):536-43. Epub 2016 Feb 4.
    • Review
    • RANKL Blockade May Aid Breast Cancer Prevention in High-Risk Patients.
    • [No authors listed]
    • Cancer Discov. 2016 Aug;6(8):816. doi: 10.1158/2159-8290.CD-RW2016-125. Epub 2016 Jul 8.
    • RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    • Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ.
    • Nat Med. 2016 Aug;22(8):933-9. doi: 10.1038/nm.4118. Epub 2016 Jun 20.
    • Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
    • Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A.
    • Oncotarget. 2016 Jul 19;7(29):45317-45330. doi: 10.18632/oncotarget.9638.
    • RANKL/RANK control Brca1 mutation-driven mammary tumors.
    • Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.
    • Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.

    Related:

    Prevention of breast cancer by RANKL/RANK blockade.

    • Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
    • Tuohy VK, Jaini R, Johnson JM, Loya MG, Wilk D, Downs-Kelly E, Mazumder S.
    • Cancers (Basel). 2016 Jun 16;8(6). pii: E56. doi: 10.3390/cancers8060056.
    • What is new in the surgical management and prevention of breast cancer?
    • Spillane AJ.
    • Med J Aust. 2016 May 2;204(8):311-4.
    • [Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
    • Sénéchal C, Reyal F, Callet N, This P, Noguès C, Stoppa-Lyonnet D, Fourme E.
    • Bull Cancer. 2016 Mar;103(3):273-81. doi: 10.1016/j.bulcan.2016.01.001. Epub 2016 Feb 3.
    • Review, [Article in French]
    • Influence of Personal Exposure to the Cancer of a Loved One on the Breast Cancer Prevention Decisions of High Risk Women.
    • Padamsee TJ, Muraveva A, Wills C, Yee L, Paskett E.
    • Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):561. 40th Annual (2016) ASPO meeting. doi: 10.1158/1055-9965.EPI-16-0090.
    • Conference abstract
    • Differing Perspectives on Breast Cancer Chemoprevention.
    • Jordan VC.
    • JAMA Oncol. 2016 Feb 1;2(2):276. doi: 10.1001/jamaoncol.2015.3906.
    • Comment, Letter

    Related:

    Viewpoint

    Tamoxifen Chemoprevention—End of the Road?

    Comment / Letter

    Reply / Letter

    Differing Perspectives on Breast Cancer Chemoprevention-Reply.

    • Pharmacogenetic Predictors of Response.
    • Hertz DL, Rae JM.
    • Adv Exp Med Biol. 2016;882:191-215. doi: 10.1007/978-3-319-22909-6_8.
    • Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation.
    • Smith SG, Side L, Meisel SF, Horne R, Cuzick J, Wardle J.
    • Public Health Genomics. 2016;19(4):239-49. doi: 10.1159/000447552. Epub 2016 Jul 12.
    • Chemoprevention or mastectomy for women at high risk of developing breast cancer.
    • Sismondi P, D'Alonzo M, Pecchio S, Bounous VE, Robba E, Biglia N.
    • Maturitas. 2015 Nov;82(3):271-3. doi: 10.1016/j.maturitas.2015.07.002. Epub 2015 Jul 26.
    • Review
    • Chemoprevention for Breast Cancer.
    • Pruthi S, Heisey RE, Bevers TB.
    • Ann Surg Oncol. 2015 Oct;22(10):3230-5. doi: 10.1245/s10434-015-4715-9. Epub 2015 Jul 23.
    • Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
    • Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.
    • Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.
    • Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    • Reimers LL, Sivasubramanian PS, Hershman D, Terry MB, Greenlee H, Campbell J, Kalinsky K, Maurer M, Jayasena R, Sandoval R, Alvarez M, Crew KD.
    • Breast J. 2015 Jul-Aug;21(4):377-86. doi: 10.1111/tbj.12418. Epub 2015 Apr 16.
    • A Rare Case of BRCA2-Associated Breast Cancer in Pregnancy.
    • Leidhin CN, Heeney A, Connolly C, Swan N, Foster A, Geraghty J.
    • Ir Med J. 2015 Jul-Aug;108(7):217-8.
    • Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
    • Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S.
    • Breast Cancer. 2015 Jul;22(4):327-34. doi: 10.1007/s12282-015-0619-6. Epub 2015 May 30.
    • Meta-Analysis
    • Breast Cancer Risk Reduction, Version 2.2015.
    • Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.
    • Practice guideline
    • Barriers to the Use of Breast Cancer Risk Reduction Therapies.
    • Bambhroliya A, Chavez-MacGregor M, Brewster AM.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):927-35.
    • Clinical management of women at high risk of breast cancer.
    • Wuttke M, Phillips KA.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):6-13. doi: 10.1097/GCO.0000000000000140.
    • Review
    • Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction.
    • Chapman JS, Jacoby V, Chen LM.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):40-4. doi: 10.1097/GCO.0000000000000146.
    • Review
    • Update on breast cancer risk prediction and prevention.
    • Sestak I, Cuzick J.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):92-7. doi: 10.1097/GCO.0000000000000153.
    • Review
    • A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
    • Vachon CM, Schaid DJ, Ingle JN, Wickerham DL, Kubo M, Mushiroda T, Goetz MP, Carlson EE, Paik S, Wolmark N, Nakamura Y, Wang L, Weinshilboum R, Couch FJ.
    • Breast Cancer Res Treat. 2015 Jan;149(2):517-23. doi: 10.1007/s10549-014-3175-4. Epub 2015 Jan 10.
    • Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers.
    • Maryam Nemati Shafaee, Angelica M. Gutierrez-Barrera, Heather Y. Lin, Banu Arun.
    • J Clin Oncol 33, 2015 (suppl 28S; abstr 3); 2015 Breast Cancer Symposium.
    • Conference Abstract

    Related:

    Press: Aromatase Inhibitors Reduce Contralateral Breast Cancer Risk in BRCA Mutation Carriers. (Oncotherapy Network)

    • Risk-benefit profiles of women using tamoxifen for chemoprevention.
    • Nichols HB, DeRoo LA, Scharf DR, Sandler DP.
    • J Natl Cancer Inst. 2014 Dec 3;107(1):354. doi: 10.1093/jnci/dju354. Print 2015 Jan.

    Related:

    Editorial, Comment:

    Breast cancer chemoprevention: the saga of underuse continues.

    • Proposal on Raloxifene use after prophylactic salpingo-oophorectomy in BRCA1-2: hypothesis and rationale.
    • Gizzo S, Noventa M, Saccardi C, Litta P, D'Antona D, Nardelli GB.
    • Eur J Cancer Prev. 2014 Nov;23(6):514-5. doi: 10.1097/CEJ.0000000000000003.
    • Letter
    • Screening and Nonsurgical Methods of Prevention for Women at High Risk for Breast Cancer.
    • Victoria Seewaldt
    • FORCE. Be Empowered Webinars. 2014 Oct 22.
    • Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention.
    • Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, Astley S, Wilson M, Ainsworth J, Cuzick J, Buchan I, Donnelly LS, Howell A.
    • Cancer Prev Res (Phila). 2014 Oct;7(10):993-1001. doi: 10.1158/1940-6207.CAPR-14-0037. Epub 2014 Jul 21.
    • Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
    • Davidson BA, Moorman PG.
    • Expert Opin Drug Saf. 2014 Oct;13(10):1375-82. doi: 10.1517/14740338.2014.951327. Epub 2014 Aug 22.
    • Review
    • Risk determination and prevention of breast cancer.
    • Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN.
    • Breast Cancer Res. 2014 Sep 28;16(5):446. doi: 10.1186/s13058-014-0446-2.
    • BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.
    • Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P, Narod SA.
    • Br J Cancer. 2014 Sep 23;111(7):1269-1274. doi: 10.1038/bjc.2014.391. Epub 2014 Jul 15.
    • Hormonal prevention of breast cancer.
    • Thomin A, Friszer S, Fajac A, Daraï É, Chabbert-Buffet N.
    • Ann Endocrinol (Paris). 2014 Jul;75(3):148-55. doi: 10.1016/j.ando.2014.04.012. Epub 2014 Jul 2.
    • Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Breast Cancer Res Treat. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21.
    • Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory.
    • Ralph AF, Ager B, Bell ML, Collins IM, Andrews L, Tucker K, Phillips KA, Butow P.
    • Patient Educ Couns. 2014 Jul;96(1):106-12. doi: 10.1016/j.pec.2014.04.011. Epub 2014 Apr 28.
    • Current strategies for the prevention of breast cancer.
    • Advani P, Moreno-Aspitia A.
    • Breast Cancer (Dove Med Press). 2014 May 2;6:59-71. doi: 10.2147/BCTT.S39114. eCollection 2014.
    • Tools of the trade: individualized breast cancer risk assessment.
    • Millstine D, David P, Pruthi S.
    • J Womens Health (Larchmt). 2014 May;23(5):434-6. doi: 10.1089/jwh.2014.4761. Epub 2014 Apr 7.
    • Management of women at high risk of breast cancer.
    • Armstrong AC, Evans GD.
    • BMJ. 2014 Apr 28;348:g2756. doi: 10.1136/bmj.g2756.
    • Review
    • Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.
    • Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, Juraskova I, Stavrinos P, Dawe S, Cuzick J, Howell A.
    • Br J Cancer. 2014 Apr 2;110(7):1681-7. doi: 10.1038/bjc.2014.109. Epub 2014 Mar 4.
    • Age-Related Decline in DNA Repair Function Explains Diminished Ovarian Reserve, Earlier Menopause, and Possible Oocyte Vulnerability to Chemotherapy in Women With BRCA Mutations.
    • Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S.
    • J Clin Oncol. 2014 Apr 1;32(10):1093-4. doi: 10.1200/JCO.2013.53.5369. Epub 2014 Feb 18.

    Related:

    Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation.

    • Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.
    • Green LE, Dinh TA, Hinds DA, Walser BL, Allman R.
    • Appl Health Econ Health Policy. 2014 Apr;12(2):203-17. doi: 10.1007/s40258-014-0089-6.
    • Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
    • Valachis A, Nearchou AD, Lind P.
    • Breast Cancer Res Treat. 2014 Apr;144(3):443-55. doi: 10.1007/s10549-014-2890-1. Epub 2014 Feb 25.
    • Meta-Analysis, Review
    • Breast cancer chemoprevention: little progress in practice?
    • Cameron DA.
    • Lancet. 2014 Mar 22;383(9922):1018-20. doi: 10.1016/S0140-6736(13)62555-6. Epub 2013 Dec 12.

    Related:

    Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

    • Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    • Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators.
    • Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12.

    Related:

    Comment:

    Breast cancer chemoprevention: little progress in practice?

    • Affordable Care Act to Cover Chemoprevention for Women at High Risk for Breast Cancer.
    • Alice Goodman.
    • The ASCO Post, 2014 Mar 15.
    • Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?
    • Phillips KA, Lindeman GJ.
    • Future Oncol. 2014 Mar;10(4):499-502. doi: 10.2217/fon.13.278.

    Related:

    Medscape-style free full text: Breast Cancer Prevention for BRCA1 and BRCA2 Mutation Carriers: Is There a Role for Tamoxifen? (Medscape)

    • Bilateral breast cancers.
    • Narod SA.
    • Nat Rev Clin Oncol. 2014 Mar;11(3):157-66. doi: 10.1038/nrclinonc.2014.3. Epub 2014 Feb 4.
    • Review
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.
    • Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.
    • Ann Intern Med. 2014 Feb 18;160(4):255-66.
    • Assessing the Genetic Risk for BRCA-Related Breast or Ovarian Cancer in Women: Recommendations From the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4). doi: 10.7326/P14-9008.

    Related:

    Systematic Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.
    • Moyer VA; U.S. Preventive Services Task Force.
    • Ann Intern Med. 2014 Feb 18;160(4):271-81.

    Related:

    Patient Education Handout:

    Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.

    • Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4):I-16.

    Related:

    Practice Guideline:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.

    • Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer.
    • Province MA, Klein TE; International Tamoxifen Pharmacogenomics Consortium.
    • J Natl Cancer Inst. 2014 Feb 1;106(2):djt379. doi: 10.1093/jnci/djt379. Epub 2014 Jan 9.

    Related:

    Letter, Reply:

    Response.

    • Risk management options elected by women after testing positive for a BRCA mutation.
    • Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.
    • Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.
    • Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
    • Brewer NT, Defrank JT, Chiu WK, Ibrahim JG, Walko CM, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, Irvin WJ Jr.
    • Public Health Genomics. [2014 Feb;]17(1):43-7. doi: 10.1159/000356565. Epub 2014 Jan 22.
    • Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Kim-Sing C, Ghadirian P, Sun P, Narod S.
    • Clin Genet. 2014 Jan;85(1):21-30. doi: 10.1111/cge.12233. Epub 2013 Aug 26.
    • Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
    • Singer C, Muhr D, Rappaport C, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Pfeiler G, Berger A, Sun P, Narod S.
    • Clin Genet. 2014 Jan;85(1):72-5. doi: 10.1111/cge.12216. Epub 2013 Jul 16.
    • Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.
    • Moyer VA; U.S. Preventive Services Task Force.
    • Ann Intern Med. 2013 Nov 19;159(10):698-708. doi: 10.7326/0003-4819-159-10-201311190-00717.

    Related:

    Patient Education Handout:

    Summaries for patients. Using medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force.

    • Summaries for patients. Using medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2013 Nov 19;159(10):I-28.

    Related:

    Practice Guideline:

    Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.

    • Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.
    • Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA.
    • J Clin Oncol. 2013 Nov 1;31(31):3914-9. doi: 10.1200/JCO.2012.47.7893. Epub 2013 Aug 26.

    Related:

    Letter, Comment:

    Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations.

    • Acceptability of chemoprevention trials in high-risk subjects.
    • Bonanni B, Lazzeroni M.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii42-viii46. doi: 10.1093/annonc/mdt328.
    • Alternatives to risk-reducing surgery for ovarian cancer.
    • Gadducci A, Sergiampietri C, Tana R.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii47-viii53. doi: 10.1093/annonc/mdt311.
    • A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
    • Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW.
    • Breast Cancer Res Treat. 2013 Nov;142(2):389-98. doi: 10.1007/s10549-013-2739-z. Epub 2013 Oct 29.
    • BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
    • Buckley NE, Nic An Tsaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.
    • Nucleic Acids Res. 2013 Oct 1;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.
    • Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.
    • [No author given]
    • U.S. Preventive Services Task Force (USPSTF). 2013 Sep 24.
    • CYP2D6 genotyping and the use of tamoxifen in breast cancer.
    • Berry D.
    • J Natl Cancer Inst. 2013 Sep 4;105(17):1267-9. doi: 10.1093/jnci/djt221. Epub 2013 Aug 19.

    Related:

    See PubMed abstract for multiple related items.

    • Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
    • Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C.
    • J Natl Cancer Inst. 2013 Sep 4;105(17):1332-4. doi: 10.1093/jnci/djt204. Epub 2013 Aug 19.

    Related:

    See PubMed abstract for multiple related items.

    • C3-3: Using the Electronic Health Record and the National Cancer Institute’s Breast Cancer Risk Assessment (SAS) Macro to Identify Women at Increased Risk for Breast Cancer.
    • Leader J, Bengier A, Darer J, Stark A, Vogel V.
    • Clinical Medicine & Research. 2013 Sep 1;11(3):150. doi: 10.3121/cmr.2013.1176.c3-3.
    • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    • Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, Olsson HL, Jakubowska A, Olah E, Gerdes AM, Foretova L, Hopper JL.
    • J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5.

    Related:

    Press: Tamoxifen Cuts Risk for Breast Cancer in BRCA Carriers. (Medscape)

    Press: Tamoxifen for prevention in high-risk breast cancer. (Medical News Today)

    Press: In BRCA, Tamoxifen May Reduce Contralateral Breast Cancer Risk. (Clinical Oncology News)

    • Use of pharmacologic interventions for breast cancer risk reduction: american society of clinical oncology clinical practice guideline.
    • Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM.
    • J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8.
    • Scanning for clues to better use selective estrogen receptor modulators.
    • Machiela MJ, Chanock SJ.
    • Cancer Discov. 2013 Jul;3(7):728-9. doi: 10.1158/2159-8290.CD-13-0251.
    • Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
    • Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, Goetz MP, Ames MM, Jenkins GD, Batzler A, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM.
    • Cancer Discov. 2013 Jul;3(7):812-25. doi: 10.1158/2159-8290.CD-13-0038. Epub 2013 Jun 13.
    • The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study.
    • Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA; Hereditary Breast Cancer Study Group.
    • Gynecol Oncol. 2013 Jul;130(1):127-31. doi: 10.1016/j.ygyno.2013.03.027. Epub 2013 Apr 3.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: BRCA mutations and endometrial cancer

    Subject: Article request

    • NICE recommends preventive drugs for breast cancer.
    • Wise J.
    • BMJ. 2013 Jun 25;346:f4116. doi: 10.1136/bmj.f4116.
    • News
    • Drugs to be offered to women at high risk of breast cancer.
    • [No author given]
    • NHS. News. 2013 Jun 6.
    • Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer.
    • Banegas MP, McClure JB, Barlow WE, Ubel PA, Smith DM, Zikmund-Fisher BJ, Greene SM, Fagerlin A.
    • Patient Educ Couns. 2013 Jun;91(3):364-71. doi: 10.1016/j.pec.2012.12.014. Epub 2013 Feb 8.
    • Breast cancer prevention: SERMs come of age.
    • Howell A, Evans DG.
    • Lancet. 2013 May 25;381(9880):1795-7. doi: 10.1016/S0140-6736(13)60443-2. Epub 2013 Apr 30.

    Related:

    Meta-Analysis, Review:

    Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

    • Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
    • Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; SERM Chemoprevention of Breast Cancer Overview Group.
    • Lancet. 2013 May 25;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3. Epub 2013 Apr 30.

    Related:

    Comment:

    Breast cancer prevention: SERMs come of age.

    Comment:

    Meta-analysis: selective estrogen-receptor modulators reduce breast cancer incidence.

    • Use of medications to reduce risk for primary breast cancer: a systematic review for the u.s. Preventive services task force.
    • Nelson HD, Smith ME, Griffin JC, Fu R.
    • Ann Intern Med. 2013 Apr 16;158(8):604-14. doi: 10.7326/0003-4819-158-8-201304160-00005.

    Related:

    News:

    Breast cancer drugs should be offered to healthy but high risk women, US panel concludes.

    Press: Chemoprevention for Women at High Risk for Breast Cancer. (Medscape)

    • Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer.
    • Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT Jr, Sullivan ME, Hansen N, Bethke K, Zalles CM, Khan SA.
    • Cancer Prev Res (Phila). 2013 Apr;6(4):321-30. doi: 10.1158/1940-6207.CAPR-12-0304. Epub 2013 Mar 19.

    Related:

    Press: Breast cancer gene test could allow preventive treatment. (The Telegraph)

    • The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.
    • Promkan M, Dakeng S, Chakrabarty S, Bögler O, Patmasiriwat P.
    • PLoS One. 2013;8(2):e55732. doi: 10.1371/journal.pone.0055732. Epub 2013 Feb 5.
    • Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
    • Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.
    • J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.

    Related:

    See PubMed abstract for multiple related items.

    • Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
    • Korfage IJ, Fuhrel-Forbis A, Ubel PA, Zikmund-Fisher BJ, Greene SM, McClure JB, Smith DM, Alford SH, Fagerlin A.
    • Breast Cancer Res. 2013;15(5):R74.

    Related:

    Comment, Editorial:

    Decision aids for breast cancer chemoprevention.

    • Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.
    • Li J, Czene K, Brauch H, Schroth W, Saladores P, Li Y, Humphreys K, Hall P.
    • Breast Cancer Res. 2013;15(5):R93.
    • Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.
    • Brooks JD, Teraoka SN, Malone KE, Haile RW, Bernstein L, Lynch CF, Mellemkjær L, Duggan DJ, Reiner AS, Concannon P, Schiermeyer K, Lewinger JP; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC.
    • Int J Mol Epidemiol Genet. 2013;4(1):35-48. Epub 2013 Mar 18.
    • Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.
    • Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Casadio C, Jemos C, Pizzamiglio M, Cortesi L, Radice D, Bonanni B.
    • BMC Cancer. 2012 Dec 5;12:575. doi: 10.1186/1471-2407-12-575.
    • BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
    • Martinez-Outschoorn UE, Balliet R, Lin Z, Whitaker-Menezes D, Birbe RC, Bombonati A, Pavlides S, Lamb R, Sneddon S, Howell A, Sotgia F, Lisanti MP.
    • Cell Cycle. 2012 Dec 1;11(23):4402-13. doi: 10.4161/cc.22776. Epub 2012 Nov 21.
    • Hereditary ovarian cancer and two-compartment tumor metabolism: Epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.
    • Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP.
    • Cell Cycle. 2012 Nov 15;11(22):4152-66. doi: 10.4161/cc.22226. Epub 2012 Oct 9.
    • PPARγ agonists target aromatase via both PGE2 and BRCA1.
    • Margalit O, Wang D, Dubois RN.
    • Cancer Prev Res (Phila). 2012 Oct;5(10):1169-72. doi: 10.1158/1940-6207.CAPR-12-0365.
    • Prevention of breast cancer in the context of a national breast screening programme.
    • Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J, Evans DG.
    • J Intern Med. 2012 Apr;271(4):321-30. doi: 10.1111/j.1365-2796.2012.02525.x.
    • Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
    • Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP, Tennevet I, Chabbert-Buffet N, This P, Baudry K, Lemonnier J, Roca L, Mijonnet S, Gesta P, Chiesa J, Dreyfus H, Vennin P, Delnatte C, Bignon YJ, Lortholary A, Prieur F, Gladieff L, Lesur A, Clough KB, Nogues C, Martin AL; French Federation of Cancer Centres (FNCLCC).
    • Fam Cancer. 2012 Mar;11(1):77-84. doi: 10.1007/s10689-011-9484-4.
    • High-Risk Surveillance for Breast Cancer.
    • Christopher Flowers.
    • FORCE. Be Empowered Webinars. 2012 Feb 22.
    • Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.
    • Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.
    • CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.
    • Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT.
    • Cancer Prev Res (Phila). 2012 Jan;5(1):89-97. doi: 10.1158/1940-6207.CAPR-11-0359. Epub 2011 Sep 20.
    • Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    • Cazzaniga M, Varricchio C, Montefrancesco C, Feroce I, Guerrieri-Gonzaga A.
    • J Biomed Biotechnol. 2012;2012:172897. doi: 10.1155/2012/172897. Epub 2012 Mar 5.